Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

August 19, 2025 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company's ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Members of Napo's Scientific Advisory Board will join Napo and Jaguar representatives at the meeting."We're...

Read more

Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins

August 19, 2025 9:00 AM

Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.The peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm...

Read more

Tenon(R) Medical Announces the Full Market Launch of the Catamaran(R) SE SI Joint Fusion System

August 19, 2025 8:30 AM

Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain sacro-pelvic disorders, today announced the full commercial market launch of its new Catamaran® SE SI Joint Fusion System. The Catamaran SE Fixation Device expands the Company's implant portfolio, providing physicians with a smaller implant option for sacroiliac (SI) joint fusion procedures.The Catamaran SE implant...

Read more

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

August 19, 2025 8:30 AM

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the successful completion of the Single Ascending Dose (SAD) portion of its ongoing Phase 1 clinical trial evaluating oral Ketamir-2. The study, conducted at the Hadassah Clinical Research Center in Israel under the direction of...

Read more

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

August 19, 2025 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced that Geoff Birkett, Chief Commercial Officer of Ensysce, will chair the Fierce New Product Planning Summit 2025, held September 8-11, 2025 at the Pennsylvania Convention Center in Philadelphia.Mr. Birkett, recognized for his expertise in product launches and commercial strategy,...

Read more

Black Book Research Outlines Path for U.S. Healthcare Stakeholders to Support Ukraine's Hospital Recovery

August 19, 2025 7:30 AM

Black Book Research has released the results of a flash survey conducted to provide U.S. healthcare stakeholders with actionable guidance on how to participate in Ukraine's hospital recovery. The study was initiated after repeated requests from American vendors, hospital leaders, and investors for clear information on procurement processes, financing mechanisms, and partnership opportunities.Earlier Black Book outreach in Q1 2025 showed that...

Read more

Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

August 19, 2025 6:30 AM

Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, announced today a new strategic partnership with VerticalVet, one of the veterinary industry's most respected Group Purchasing Organizations (GPOs), supporting over 2,600 independent veterinary practices across the United States. This two-year agreement establishes...

Read more

Pres. Trump's Chance to Fix DEA's Marijuana Policy Failures: Rescheduling?

August 19, 2025 5:00 AM

For too long, the DEA has written rules, then ignored them. It has promised science, then sidelined it. Patients with Huntington's disease and Multiple Sclerosis have been told to wait, while recreational markets flourish outside federal control.President Trump's consideration of rescheduling marijuana is the first serious chance in decades to break this cycle. The challenge now is ensuring that reform does not just enrich Big Weed - but instead...

Read more

AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs

August 19, 2025 4:20 AM

AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, invites you to a live broadcast event on August 27 at 2:00 PM around the phase II drug candidate ACD440, with Dimitrina Chukova from Karolinska Institutet, Stockholm, Sweden, as an invited guest speaker.The purpose of the event is to present the background and...

Read more

Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025

August 18, 2025 5:30 PM

Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present Financial Results for the quarter ended June 30, 2025 via conference call on August 21, 2025 at 8:30 am Eastern Time. The Financials for the quarter ended June 30, 2025 will be filed after market close on...

Read more

Luna Diabetes Raises Series A Financing to Advance its Automated Insulin Delivery Solution For Insulin Pen Users

August 18, 2025 1:40 PM

Luna Health Inc., a medical device company pioneering a first-of-its-kind method of insulin delivery for insulin pen users, today announced the closing of its $23.6M Series A financing led by Vensana Capital, with participation from the Swiss Diabetes Venture Fund, Ascensia Diabetes Care, Winklevoss Capital, and other prominent investors with deep expertise in diabetes technology and value creation. The funding will accelerate development of...

Read more

Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer

August 18, 2025 12:45 PM

Cantargia (STO:CANTA) today announced that it has appointed the highly experienced biotechnology executive and two-time CEO, Dr Hilde Steineger, as its new Chief Executive Officer. Hilde will be joining Cantargia from NorthSea Therapeutics (NorthSea), where she has been Co-Founder and the Chief Operating Officer since 2017, as well as the CEO of Staten Biotechnology, since 2017, where she led a $480M deal with Novo Nordisk."I am thrilled to join...

Read more

The Assistance Fund Opens New Program for Bronchiectasis

August 18, 2025 12:00 PM

The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new copay assistance program for people living with bronchiectasis. The program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment, such as copays, coinsurance, and deductibles.Bronchiectasis is a chronic lung disease...

Read more

Society of Interventional Oncology Announces First Site Approved for Enrollment in TRIBUTE Trial

August 18, 2025 11:00 AM

The Society of Interventional Oncology (SIO) proudly announces that the Washington University School of Medicine in St. Louis, MO, USA, has been the first site approved and activated for enrollment in the society's second clinical trial, TRIBUTE: A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy. The Washington University School of Medicine site study...

Read more

Australia's Top Healthcare IT Vendors Named by Black Book Research in 2025 Annual User Rankings

August 18, 2025 10:30 AM

Black Book Research today announced the 2025 top-rated healthcare IT vendors in Australia, recognizing leaders across 13 categories of digital health and hospital information systems. The results were unveiled live at the HIC 2025 conference and on the event website, as more than 1,500 healthcare leaders, clinicians, and technology suppliers gather at the Melbourne Convention and Exhibition Centre.The annual survey drew 864 validated responses...

Read more

Ambience Healthcare Unveils Chart Chat: The First AI Copilot Built Into the EHR

August 18, 2025 10:05 AM

Ambience Healthcare has unveiled Chart Chat, a first-of-its-kind AI copilot designed to integrate directly within Epic's electronic health record (EHR) system to give healthcare providers context-aware clinical insights. Chart Chat combines patient chart data with medical content from BMJ Best Practice and OpenAI's Reinforcement Fine Tuning (RFT) technology to create a novel intelligence layer over the EHR."This technology can fundamentally...

Read more

MDCE Subsidiary Infinite Auctions Soars with 2,500% YoY Revenue Growth in Q2 2025

August 18, 2025 9:17 AM

Medical Care Technologies Inc. (OTC Pink:MDCE) recently announced that its wholly owned subsidiary, Infinite Auctions (www.infiniteauctions.com), achieved a significant revenue milestone in the second quarter of 2025. Infinite Auctions generated $296,175 in Q2 2025 revenues, a dramatic increase compared to $11,035 in Q2 2024, representing year-over-year revenue growth of more than 2,500%.The company also confirmed strong momentum heading into...

Read more

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

August 18, 2025 8:30 AM

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced positive top-line data from its recent randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults....

Read more

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

August 18, 2025 8:30 AM

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of "sleeping" cancer cells due to viral infections. NV-387 has...

Read more

Genflow Biosciences PLC Announces Company Update on Dog Trials

August 18, 2025 2:00 AM

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In...

Read more